World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
94
Citations
39010
World Ranking
10356
National Ranking
5326

Glenn J. Jaffe publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Glenn J. Jaffe sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 506 publications — 59th percentile

59% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Glenn J. Jaffe D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Glenn J. Jaffe sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 94 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Glenn J. Jaffe is affiliated with Duke University in the United States and has a research focus primarily within the field of Medicine, with a specific emphasis on Ophthalmology. Their scholarly work extensively addresses retinal diseases and treatments, retinal imaging and analysis, and conditions affecting the retina and optic nerves. Other areas of interest include ocular diseases such as Behçet's syndrome, glaucoma and related retinal disorders, retinal development, and macular surgery.

Jaffe's publication record demonstrates a consistent contribution to notable ophthalmology-related journals. Among the frequent venues are:

  • Ophthalmology
  • Ophthalmology Retina
  • Ophthalmology Science
  • American Journal of Ophthalmology
  • Retina

Their recent papers cover specialized topics in retinal research and therapies. Notable recent publications include:

  • C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration (2020, Ophthalmology)
  • HAWK and HARRIER (2020, Ophthalmology)
  • Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab (2020, Ophthalmology)
  • Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial (2023, The Lancet)
  • Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration (2020, Ophthalmology)

Collaboration appears to be a key aspect of Jaffe's work, with frequent coauthors including Maureen G. Maguire, Frank G. Holz, Arshad M. Khanani, Charles C. Wykoff, and Daniel Martín. These collaborators have contributed to multiple publications, indicating ongoing research partnerships in related subfields.

Jaffe's research spans several subfields within Medicine, particularly:

  • Ophthalmology
  • Radiology, Nuclear Medicine and Imaging
  • Molecular Biology
  • Neurology
  • Epidemiology

The main topics covered in their work further detail their research scope:

  • Retinal Diseases and Treatments
  • Retinal Imaging and Analysis
  • Retinal and Optic Conditions
  • Ocular Diseases and Behçet's Syndrome
  • Glaucoma and retinal disorders
  • Retinal Development and Disorders
  • Retinal and Macular Surgery

Overall, Glenn J. Jaffe's scholarly contributions center on advancing understanding and treatments related to retinal health, leveraging both clinical trials and imaging technologies to address various ocular conditions within the broader framework of ophthalmology.

Best Publications

  • Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

    Daniel F Martin;Maureen G Maguire;Gui-shuang Ying

  • Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

    Daniel F. Martin;Maureen G. Maguire;Stuart L. Fine;Gui Shuang Ying

  • Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel

    Douglas A. Jabs;James T. Rosenbaum;C.Stephen Foster;Gary N. Holland

  • Intravitreal aflibercept for diabetic macular edema.

    Jean François Korobelnik;Diana V. Do;Ursula Schmidt-Erfurth;David S. Boyer

  • Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration: Ninety-Six–Week Results of the VIEW Studies

    Ursula Schmidt-Erfurth;Peter K. Kaiser;Jean François Korobelnik;David M. Brown

  • HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

    Pravin U Dugel;Adrian Koh;Yuichiro Ogura;Glenn J Jaffe

  • Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials

    Maureen G. Maguire;Daniel F. Martin;Gui shuang Ying;Glenn J. Jaffe

  • Optical coherence tomography to detect and manage retinal disease and glaucoma.

    Glenn J. Jaffe;Joseph Caprioli

  • Consensus Definition for Atrophy Associated with Age-Related Macular Degeneration on OCT: Classification of Atrophy Report 3.

    Srinivas R. Sadda;Robyn Guymer;Frank G. Holz;Steffen Schmitz-Valckenberg

  • Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.

    David M. Brown;Ursula Schmidt-Erfurth;Diana V. Do;Frank G. Holz

  • Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study.

    Glenn J. Jaffe;Daniel Martin;David Callanan;P. Andrew Pearson

  • Adalimumab in Patients with Active Noninfectious Uveitis

    Glenn J Jaffe;Andrew David Dick;Andrew David Dick;Antoine P Brézin;Quan Dong Nguyen

  • Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data: Consensus on Neovascular Age-Related Macular Degeneration Nomenclature Study Group

    Richard F. Spaide;Glenn J. Jaffe;David Sarraf;K. Bailey Freund

  • Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.

    Juan E. Grunwald;Ebenezer Daniel;Jiayan Huang;Gui Shuang Ying

  • Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

    Quan Dong Nguyen;Pauline T. Merrill;Glenn J. Jaffe;Andrew D. Dick;Andrew D. Dick

  • cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium.

    S Haskill;G Martin;L Van Le;J Morris

  • Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies

    Jeffrey S. Heier;Jean François Korobelnik;David M. Brown;Ursula Schmidt-Erfurth

  • Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results.

    D G Callanan;G J Jaffe;D F Martin;P A Pearson

  • Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration

    Kang Zhang;Jill J. Hopkins;Jeffrey S. Heier;David G. Birch

  • Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration

    Gui Shuang Ying;Jiayan Huang;Maureen G. Maguire;Glenn J. Jaffe

Frequent Co-Authors

Cynthia A. Toth
Cynthia A. Toth Duke University
Maureen G. Maguire
Maureen G. Maguire University of Pennsylvania
Sina Farsiu
Sina Farsiu Duke University
Frank G. Holz
Frank G. Holz University of Bonn
Frederick L. Ferris
Frederick L. Ferris National Institutes of Health
Emily Y. Chew
Emily Y. Chew National Institutes of Health
Andrew D. Dick
Andrew D. Dick University of Bristol
Jennifer E. Thorne
Jennifer E. Thorne Johns Hopkins University
Srinivas R. Sadda
Srinivas R. Sadda University of California, Los Angeles
Ursula Schmidt-Erfurth
Ursula Schmidt-Erfurth Medical University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Considering a future in medicine doesn’t always mean pursuing a traditional MD in the USA. Many students explore flexible, affordable online programs that open doors to a variety of healthcare careers. For instance, aspiring nurse practitioners can save both time and money by enrolling in one of the cheapest dnp online programs available, earning a Doctor of Nursing Practice degree from home.

If pharmacy is more your focus, a number of accredited online pharmacist programs allow you to study for a PharmD while balancing work and family obligations. Beyond clinical roles, there are also opportunities in health administration and data management. Those interested in healthcare systems can check out him programs to build expertise in electronic medical records and compliance.

For students seeking a fast track into the healthcare field, online certification in medical coding and billing is a popular choice. The medical billing and coding certification cost is often lower than other healthcare educational paths, with short courses that qualify graduates for in-demand entry-level positions. These online options provide flexible and diverse pathways in the ever-growing US healthcare sector.

Best Scientists Citing Glenn J. Jaffe

Trending Scientists

Recently Published Articles